Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome
-
Published:2021-09
Issue:
Volume:85
Page:138-146
-
ISSN:1389-9457
-
Container-title:Sleep Medicine
-
language:en
-
Short-container-title:Sleep Medicine
Author:
Inoue YuichiORCID,
Hirata Koichi,
Hoshino Yuya,
Yamaguchi Yusuke
Reference48 articles.
1. Diagnostic criteria,2012
2. [Standardized neurological treatment: restless legs syndrome]. 標準的神経治療：Restless legs症候群,2012
3. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation;Garcia-Borreguero;Sleep Med,2016
4. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study;Inoue;Curr Med Res Opin,2013
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献